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Abstract 
Zeolites are hydrated silicates of aluminium that have been very useful in many 
industry because of its microporous property, absorbance ability and  ion exchange 
capacity. It is currently viewed as a potential adjuvant in cancer therapy due to its 
ability to inhibit the proliferation of cancer cells. Research on natural zeolite 
clinoptilolite application as anticancer agent has been proven by others. However, the 
effect of other types of zeolite on cancer cells is still uncertain. This study is 
performed to determine the effects of zeolite X and Y on cancer cell lines 
proliferation in vitro. Cancer cell lines HeLa, AsPC-1 and 911 cells were cultured in 
designated medium treated with zeolite X and zeolite Y at the concentration of 5 
mg/ml and 50 mg/ml. Fetal Bovine Serum (FBS) concentrations were modified to 
5%, 10%, 15% and 20%. After 72 hours incubation, the efficacy of zeolite to treat 
cancer cell lines were measured by means of cell viability test via MTT assay. 
Overall results showed that cancer cell lines cultivated in the medium treated with 50 
mg/ml of zeolite X and 5% FBS exhibited the highest inhibition of cell proliferation 
and decrease in cell viability. This finding provides preliminary information in the 
study of determining the potential use of zeolite as anticancer agent for alternative or 
complementary therapy.  
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1. INTRODUCTION 
 
Cancer is an uncontrolled growth and spread of abnormal cells caused by several 
intrinsic and extrinsic factors such as inherited mutations, hormones, immune 
conditions, chemicals, radiations and infectious agents. It is one of the major diseases 
in the world that are linked to a high death toll. According to the latest statistics in 
2008 from the International Agency for Research on Cancer (IARC), the two most 
common types of new cancer cases and deaths among South East Asian men are lung 
cancer (19.8%) and liver cancer (15.1%) while breast cancer (22.4%) and cervical 
cancer (11.4%) remain as the top two cancer types in South East Asian women [1]. 
 
Cancer is usually treated by surgery, radiation therapy, chemotherapy and 
hormone therapy. Besides that, there are a few other existing options in cancer 
treatments that are still under research or yet to be proven clinically, for example 
gene therapy and other complementary therapies such as the use of plants, fruits or 
herbal extracts. Unfortunately, there are still many limitations to the current varieties 
of cancer treatment. One of the main constraint is side effects, especially after a 
chemotherapy. Swelling, fatigue, nausea, vomiting and headache are the usual 
complaints acknowledged among cancer patients. The possibility of recurrence and 
the grief of losing an organ after a surgery are some added constraints in the present 
cancer therapies. 
 
Zeolites are hydrated aluminium silicates that are widely used in many 
industries and agriculture. Additionally, zeolites have been useful in biomedical 
application such as in the treatment of diabetes mellitus, antidiarrheal agents, 
hemodialysis, bone formation and drug delivery [2]. Earlier in the last decade, 
tribomechanically micronized zeolite was revealed to have anticancer and 
antioxidative effect on several human cell lines [2]-[3]. Natural clinoptilolite is 
viewed as a potential adjuvant in cancer treatment due to its ability to inhibit the 
proliferation of cancer cells [2], [4]. However, the effect of other types of zeolite on 
cancer cells is still uncertain. This study is performed to determine the effects of 
zeolite X and Y on cancer cell lines proliferation in vitro. 
 
 
2. MATERIALS AND METHODS 
 
Complete growth medium of Dulbecco’s modified Eagle’s medium (DMEM) and 
Roswell Park Memorial Institute medium (RPMI 1640) were used for cell culture. 
MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
yellow tetrazole) prepared using MTT powder by Sigma-Aldrich was used for cell 
viability assay. MTT solvent was prepared using hydrochloric acid and isopropanol. 
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2.1 Cell Culture 
 
Three cancer cell lines were used in this study; cervical carcinoma (HeLa), human 
pancreatic tumor (AsPC-1) and human embryonic retinoblasts (HER) cells (911), 
which were obtained from American Type Culture Collection (ATCC) Biological 
Resource Centre. The cells were grown in tissue culture flasks containing media 
DMEM or RPMI 1640, supplemented with different concentrations (5%, 10%, 15%, 
20%) of fetal bovine serum (FBS), 2% L-glutamine, 1% penicillin-streptomycin in a 
humidified atmosphere with 5% CO2 at 37°C. Then, the cells were isolated and 200 
μl of the cell suspension were seeded into 96-well plates (1x104 cells/ml) using the 
appropriate medium in triplicates. Upon reaching 60% to 80% confluency, cell 
medium in the 96-well plates was removed and replaced with medium which was 
pre-treated with 5 mg/ml or 50 mg/ml zeolite (zeolite X, zeolite Y). Cells were then 
incubated for 24 to 72 hours in a CO2 incubator.  
 
2.2 Zeolite Treatment of the Media 
 
Zeolites X and Y were weighed and added into each represented serum-free media at 
5 mg/ml and 50 mg/ml. The solution was autoclaved for 20 minutes at 121°C, liquid 
cycle. After that, the solution was centrifuged at 26, 000 rpm for 5 minutes. The 
solution was then separated from its suspension. Finally, different concentrations 
(5%, 10%, 15%, 20%) of fetal bovine serum (FBS), 2% L-glutamine and 1% 
penicillin-streptomycin were supplemented into the treated-media. 
 
2.3 Cell Viability Assay 
 
After 72 hours of incubation, the treated-medium was removed and 90 μl complete 
growth medium was added in each 96-well together with 10 μl of MTT solution per 
well. The cells were then incubated for 4 hours in CO2 incubator at 37°C in dark. 
Later, MTT solvent was added and the results were read by ELISA micro-well plate 
reader at 575 nm.  
          
 
3. RESULTS AND DISCUSSION 
 
The data collected from this study were analysed accordingly using ANOVA 
Tukey’s test. The analysis were performed between the data of the control and the 
data from the different FBS concentrations. Significant differences were shown when 
p ≤ 0.05.  
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3.1 Treatment of HeLa with Zeolite X and Y  
 
Zeolite X showed a higher cell growth inhibition than zeolite Y at 5 mg/ml zeolite 
with 15% and 20% FBS (Fig. 1a). On the other hand, zeolite Y showed a higher 
inhibition than zeolite X at 5 mg/ml zeolite with 5% FBS and 10% FBS. Statistically, 
treatment using zeolite X at 5 mg/ml showed no significant difference between the 
control and any of the FBS concentrations used. A significant difference can only be 
seen when HeLa was treated using 5 mg/ml of zeolite Y at 15% FBS in compare to 
other FBS concentrations. 
 
 
 
Figure 1: Inhibition of HeLa using Zeolite X with (a)Y (5 mg/ml) and (b) Y (50 
mg/ml). 
 
Figure 1b shows the inhibition of HeLa when treated with zeolite X and Y at 
concentration 50 mg/ml. Zeolite X showed a higher cell growth inhibition compared 
to zeolite Y. Treatment of medium using 50 mg/ml of zeolite X showed a statistically 
significant difference at 5% FBS. However, there was no significant difference 
shown between the control and any of the FBS concentrations in the medium treated 
with 50 mg/ml of zeolite Y. 
 
3.2 Treatment of 911 with Zeolite X and Y  
 
In general, human embryonic retinoblasts (HER) cells known as 911, showed a 
higher decrease in viability after treatment with zeolite X at 5 mg/ml compared to 
after treatment with zeolite Y at 5 mg/ml (Fig. 2a). Statistically significant difference 
between different FBS concentrations were shown in cell cultures with zeolite X 
treatment. However, treatment using zeolite Y at 5 mg/ml showed significant 
differences between the control and all the different concentrations of FBS but no 
significant differences were observed within the different FBS concentrations. 
 
(b) (a) 
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Figure 2: Inhibition of 911 using Zeolite X with (a) Y (5 mg/ml) and  (b)Y (50 
mg/ml). 
 
Zeolite X showed a higher decrease in 911 cell viability compared to zeolite 
Y at concentration 50 mg/ml (Fig. 2b). Treatment using zeolite X at 50 mg/ml 
showed significant differences between the control and all the different FBS 
concentrations but there were no significant differences among the different 
concentrations. On the other hand, a significant difference can be seen when 911 was 
treated using 50 mg/ml zeolite Y at all different FBS concentrations. 
 
3.3 Treatment of AsPC-1 with Zeolite X and Y  
 
Generally, zeolite X treatment showed a higher inhibition compared to zeolite Y 
treatment. Figure 3a shows the inhibition of AsPC-1 when treated with zeolite X and 
Y at 5 mg/ml concentration. Statistic analysis showed that the control results from 
both treatments were significantly different from the results of all their FBS 
concentrations. Zeolite Y treatment exhibited a higher inhibition of cell proliferation 
compared to zeolite X treatment at 50 mg/ml concentration (Fig. 3b). Statistic results 
for both zeolites treatment showed significant differences in all FBS concentrations. 
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Figure 3: Inhibition of AsPC-1 using Zeolite X with (a) Y (5 mg/ml) and (b) Y (50 
mg/ml). 
 
3.4 Paired sample T-test 
  
In this study, the T-test was used to compare between; (i) zeolite X and Y at 5 
mg/ml, and (ii) zeolite X and Y at 50 mg/ml. By calculation, only HeLa showed p < 
0.05, indicating that zeolite X and Y showed a significant difference at 5 mg/ml 
(Table 1).  
 
Table 1: Paired sample T-test between zeolite X and Y at 5 mg/ml. 
Zeolite X-Y 
(5 mg/ml) 
Cell Lines Sig. (p) 
HeLa 0.001 
911 0.087 
AsPC-1 0.783 
 
Nonetheless, all three cell lines at 50 mg/ml showed p < 0.05, which indicates that 
zeolite X and Y showed a significant difference for all tested cells (Table 2). 
 
Table 2: Paired sample T-test between zeolite X and Y at 50 mg/ml. 
Zeolite X-Y 
(50 mg/ml) 
Cell Lines Sig. (p) 
HeLa 0.006 
911 0.000 
AsPC-1 0.028 
 
Zeolite X was found to be a higher inhibitor than zeolite Y according to results 
obtained in this study. The reason could be because zeolite X has a higher adsorption 
property compared to zeolite Y. Commercial zeolite X from Zeolyst has a larger 
surface area of 925 m2/g compared to nanocrystalline of Zeolite Y, which is only 648 
m2/g as measured by [5]. Hence, the higher adsorption property of zeolite X than 
zeolite Y is equitable.  
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4. CONCLUSIONS 
 
Briefly, zeolite X and Y inhibited cancer cell lines proliferation and decrease the 
cells viability in vitro. Overall results showed that cancer cell lines cultivated in the 
medium treated with 50 mg/ml of zeolite X and 5% FBS exhibited the highest 
inhibition of cell proliferation and decrease in cell viability. The best cell medium for 
treatment of cancer cell lines using zeolites are the ones with low FBS concentration. 
The different results obtained when FBS concentration were manipulated proved that 
added serum in cell media influenced zeolite efficacy as anticancer adjuvant. The 
findings provide preliminary information in the study of determining the potential 
use of zeolite as anticancer agent for alternative or complementary therapy. 
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